معرفی
Zachary Yochum, MD, PhD, is a Clinical Assistant Professor in the Department of Internal Medicine at Yale School of Medicine, specializing in Medical Oncology and Hematology. His research focuses on molecular mechanisms of drug resistance in oncogene-driven cancers, particularly lung and renal cell carcinomas, with an emphasis on EMT transcription factors (TWIST1, ZEB1), HGF/MET pathways, and novel therapeutic strategies.
Yochum holds a BS from the University of Notre Dame (2012), MD and PhD from the University of Pittsburgh School of Medicine (2020). He completed residency at Brigham and Women's Hospital and a postdoctoral fellowship funded by the HHMI Medical Research Fellowship and NIH grants.
His research interests include developing targeted therapies against EGFR inhibitor resistance, immunotherapy rechallenge strategies, and understanding circRNA regulation in tumor progression. He has published widely in journals like Oncogene, Clinical Cancer Research, and The Lancet.
- Awards: HHMI Medical Research Fellowship (2014), F30 Ruth L. Kirschstein Fellowship (2017), Alpha Omega Alpha (2019)
Yochum collaborates with teams investigating tumor microenvironment interactions, MET pathway activation, and biomarker-driven clinical trials. He is part of translational research initiatives at Yale focused on precision oncology and drug resistance mechanisms.